Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cizzle Biotechnology Holdings PLC ( (GB:CIZ) ) has provided an announcement.
Cizzle Biotechnology Holdings PLC announced that its licensing partner, Cizzle Bio Inc, has appointed iGenomeDX, a COLA accredited and CLIA certified laboratory, to launch the first commercial CIZ1B biomarker test in the USA. This strategic move is part of Cizzle’s plan to achieve commercial sales of the test, which aims to improve early detection of lung cancer. The successful collaboration between Cizzle, iGenomeDX, and Cizzle Bio ensures the test meets high standards of accuracy and reliability, potentially reducing premature cancer deaths and enhancing patient outcomes.
More about Cizzle Biotechnology Holdings PLC
Cizzle Biotechnology Holdings PLC is a UK-based diagnostics developer specializing in early cancer detection tests. The company has developed the CIZ1B biomarker into a non-invasive, cost-effective blood test aimed at early detection of lung cancer. Cizzle has entered commercial royalty-bearing arrangements and collaborations with cancer care centers, and was admitted to the London Stock Exchange in May 2021.
Average Trading Volume: 1,195,485
Technical Sentiment Signal: Buy
Current Market Cap: £6.14M
For a thorough assessment of CIZ stock, go to TipRanks’ Stock Analysis page.